Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 7981 AL 7995

Conventional and Emerging Drug Targeting Sites in Alzheimer's Disease and the Role of Translational Informatics in its Diagnosis and Management

Khan KA, Esa M, Kamal Z, Ullah B, Perry G, Kamal S, Ahmad S, Hussain H, Ullah A, Shafique M.

Curr Neuropharmacol. 2025;23(14):1894-1917. doi: 10.2174/011570159X361867250313073624.

The importance of non-pharmacological interventions to improve cognitive reserve prior to the administration of a drug against the causative agent of Alzheimer's disease

Maki Y, Ubuka T, Yamane Y.

J Alzheimers Dis. 2025 Jan;103(2):358-360. doi: 10.1177/13872877241301806. Epub 2024 Dec 5.

Recent Advances in the Application of Artificial Intelligence in Alzheimer's Disease

Yao L, Ni J, Wei M, Li T, Li F, Wang T, Xiao W, Shi J, Tian J.

Curr Alzheimer Res. 2025;22(11):815-827. doi: 10.2174/0115672050410489250930175402.

PDE4D inhibitors: Opening a new era of PET diagnostics for Alzheimer's disease

Shi L, Wang X, Si H, Song W.

Neurochem Int. 2025 Jan;182:105903. doi: 10.1016/j.neuint.2024.105903. Epub 2024 Dec 6.

Effect of Social Restriction Due to the COVID-19 Pandemic on Activity of Daily Living and Disease Severity of Patients With Alzheimer Disease: Sub-analysis of a Double-blinded Noninferiority Study of Donepezil Patches and Donepezil Tablets

Nakamura Y, Omori T, Nishiyama K, Ishikawa I, Aoki H, Nagakura N.

Alzheimer Dis Assoc Disord. 2025 Jan-Mar 01;39(1):44-50. doi: 10.1097/WAD.0000000000000657. Epub 2025 Jan 31.

Anti-Amyloid Therapies for Alzheimer's Disease and Amyloid-Related Imaging Abnormalities: Implications for the Emergency Medicine Clinician

Rech MA, Carpenter CR, Aggarwal NT, Hwang U.

Ann Emerg Med. 2025 Jun;85(6):526-536. doi: 10.1016/j.annemergmed.2024.12.002. Epub 2025 Jan 17.

Long-term safety of gantenerumab in participants with Alzheimer's disease: A phase III, open-label extension study (SCarlet RoAD)

Boada M, Neve A, Das B, Wojtowicz J, Huang Z, Bullain S, Watkin M, Lott D, Bittner T, Delmar P, Klein G, Hofmann C, Kerchner GA, Smith J, Baudler M, Fontoura P, Doody RS.

J Alzheimers Dis. 2025 Jan;103(2):528-541. doi: 10.1177/13872877241303644. Epub 2024 Dec 16.

Molecular Modeling Insights on the Pharmaceuticals and Hypotheses of Alzheimer's Disease

de Castro AA, Silva HF, Garcia MVFP, Homem-de-Mello P, Ramalho TC.

Curr Med Chem. 2025;32(25):5110-5138. doi: 10.2174/0109298673318143240823064403.

Advancing Alzheimer's Diagnosis with AI-Enhanced MRI: A Review of Challenges and Implications

Batool Z, Hu S, Kamal MA, Greig NH, Shen B.

Curr Neuropharmacol. 2025;23(14):1860-1877. doi: 10.2174/011570159X353595250303064846.

Advances in Alzheimer's disease control approaches via carbon nanotubes

Cai J, Li B, Zhang J, Feng G, Liu Y, Fan H, Zheng B.

Nanomedicine (Lond). 2025 Jan;20(1):63-77. doi: 10.1080/17435889.2024.2432855. Epub 2024 Nov 28.

Novel techniques for early diagnosis and monitoring of Alzheimer's disease

Parul, Singh A, Shukla S.

Expert Rev Neurother. 2025 Jan;25(1):29-42. doi: 10.1080/14737175.2024.2415985. Epub 2024 Oct 22.

Diagnosis and Management of Alzheimer's Disease in Primary Care: A Real-World Study in Ontario, Canada

Ismail Z, Wilson M, Khalifa H, Belovich D, Shaw E, Pham T, McMullen S, Chen Y, Sadman N, Cai J, Zulkernine F, Barber D.

J Prim Care Community Health. 2025 Jan-Dec;16:21501319251363156. doi: 10.1177/21501319251363156. Epub 2025 Aug 16.

Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease

Salloway S, Wojtowicz J, Voyle N, Lane CA, Klein G, Lyons M, Rossomanno S, Mazzo F, Bullain S, Barkhof F, Bittner T, Schneider A, Grundman M, Aldea R, Boada M, Smith J, Doody R.

JAMA Neurol. 2025 Jan 1;82(1):19-29. doi: 10.1001/jamaneurol.2024.3937.

Traditional Chinese Medicine for Alzheimer's Disease: A Systematic Review and Meta-Analysis

Chen Y, Zhang D, Chen T, Zhao L, Wen L, Hou R.

Am J Chin Med. 2025;53(1):1-15. doi: 10.1142/S0192415X25500016. Epub 2025 Feb 21.

Blarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial

Macfarlane S, Grimmer T, Teo K, O'Brien TJ, Woodward M, Grunfeld J, Mander A, Brodtmann A, Brew BJ, Morris P, Short C, Kurrle S, Lai R, Bharadwaj S, Drysdale P, Sturm J, Lewis SJG, Barton D, Kalafatis C, Sharif S, Perry R, Mannering N, MacSweeney JE, Pearson S, Evans C, Krishna V, Thompson A, Munisamy M, Bhatt N, Asher A, Connell S, Lynch J, Rutgers SM, Dautzenberg PL, Prins N, Oschmann P, Frölich L, Tacik P, Peters O, Wiltfang J, Henri-Bhargava A, Smith E, Pasternak S, Frank A, Chertkow H, Ingram J, Hsiung GR, Brittain R, Tartaglia C, Cohen S, Villa LM, Gordon E, Jubault T, Guizard N, Tucker A, Kaufmann WE, Jin K, Chezem WR, Missling CU, Sabbagh MN.

J Prev Alzheimers Dis. 2025 Jan;12(1):100016. doi: 10.1016/j.tjpad.2024.100016. Epub 2025 Jan 1.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias